About This Fund
BV Healthcare Growth Innvierte I is a growth-stage healthcare investment fund managed by a joint venture between Buenavista Equity Partners (majority stake) and Columbus Venture Partners, both of which have deep specialization in the Spanish and European healthcare ecosystem. The fund completed its first close at 100 million euros in December 2024, reaching its original fundraising target, with a hard cap set at 150 million euros. The vehicle was structured under Spain's CDTI Innvierte co-investment programme, through which the Centre for Technological Development and Innovation committed 58 million euros to support the development of advanced therapies and innovative drug development in Spain.
The fund targets 10 to 12 innovative healthcare companies primarily based in Spain that have reached the stage of approaching commercialization, combining low scientific or technological risk with high growth and scalability potential. Investment tickets of up to 15 million euros are deployed across pharmaceutical and biotech products, diagnostic solutions, precision medicine, medical devices, AI and digital health applications, manufacturing scale-up projects including CRO and CDMO services, and healthcare services. The fund focuses on bridging the funding gap between late-stage R&D completion and commercial launch, a segment historically underserved by both traditional venture capital and private equity in the Spanish market, which has lacked dedicated growth capital vehicles for health technology companies.
The joint venture management team at Buenavista Equity Partners and Columbus Venture Partners brings a combined track record of 45 healthcare investments with reported net returns exceeding 30 percent IRR. BV Healthcare Growth Innvierte I's inaugural investment was in Syngoi, a CDMO specializing in synthetic DNA for advanced therapies, based in Zamudio, Bizkaia, reflecting the fund's commitment to companies at the intersection of biotechnology and industrial-scale production. Addleshaw Goddard advised Buenavista Equity Partners on the fund launch and structuring.